EP Wealth Advisors LLC Acquires 332 Shares of Incyte Co. (NASDAQ:INCY)

EP Wealth Advisors LLC lifted its stake in shares of Incyte Co. (NASDAQ:INCY) by 9.1% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 3,961 shares of the biopharmaceutical company’s stock after buying an additional 332 shares during the quarter. EP Wealth Advisors LLC’s holdings in Incyte were worth $240,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also bought and sold shares of the stock. Northwestern Mutual Wealth Management Co. lifted its holdings in shares of Incyte by 204.6% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 9,350 shares of the biopharmaceutical company’s stock worth $567,000 after purchasing an additional 6,280 shares in the last quarter. NewEdge Advisors LLC grew its holdings in shares of Incyte by 23.9% during the second quarter. NewEdge Advisors LLC now owns 23,087 shares of the biopharmaceutical company’s stock valued at $1,400,000 after buying an additional 4,456 shares during the last quarter. Creative Planning lifted its holdings in Incyte by 13.4% during the second quarter. Creative Planning now owns 21,059 shares of the biopharmaceutical company’s stock worth $1,277,000 after acquiring an additional 2,496 shares during the period. Forefront Analytics LLC boosted its position in Incyte by 11.3% in the second quarter. Forefront Analytics LLC now owns 6,158 shares of the biopharmaceutical company’s stock worth $373,000 after purchasing an additional 627 shares during the last quarter. Finally, MBB Public Markets I LLC bought a new position in Incyte in the 2nd quarter valued at $891,000. 96.97% of the stock is owned by institutional investors.

Insider Transactions at Incyte

In other Incyte news, EVP Jonathan Elliott Dickinson sold 8,450 shares of Incyte stock in a transaction dated Thursday, September 12th. The shares were sold at an average price of $62.36, for a total value of $526,942.00. Following the completion of the transaction, the executive vice president now directly owns 36,390 shares of the company’s stock, valued at approximately $2,269,280.40. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In other Incyte news, insider Thomas Tray sold 572 shares of the company’s stock in a transaction that occurred on Thursday, September 12th. The shares were sold at an average price of $62.94, for a total transaction of $36,001.68. Following the completion of the sale, the insider now directly owns 24,825 shares of the company’s stock, valued at approximately $1,562,485.50. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Jonathan Elliott Dickinson sold 8,450 shares of Incyte stock in a transaction on Thursday, September 12th. The stock was sold at an average price of $62.36, for a total transaction of $526,942.00. Following the transaction, the executive vice president now owns 36,390 shares in the company, valued at $2,269,280.40. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 34,047 shares of company stock valued at $2,225,626. Insiders own 17.50% of the company’s stock.

Analyst Ratings Changes

INCY has been the subject of a number of research reports. Wolfe Research assumed coverage on shares of Incyte in a research report on Tuesday. They set an “outperform” rating and a $84.00 target price for the company. Bank of America increased their price objective on Incyte from $66.00 to $68.00 and gave the company a “neutral” rating in a report on Monday, September 16th. JPMorgan Chase & Co. boosted their price objective on Incyte from $59.00 to $61.00 and gave the company a “neutral” rating in a research note on Wednesday, July 31st. Cantor Fitzgerald restated a “neutral” rating on shares of Incyte in a research note on Monday, September 16th. Finally, Guggenheim lifted their target price on Incyte from $86.00 to $92.00 and gave the company a “buy” rating in a report on Monday, September 16th. One investment analyst has rated the stock with a sell rating, eleven have assigned a hold rating and nine have given a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $73.83.

Incyte Stock Performance

NASDAQ:INCY opened at $67.49 on Friday. The company has a quick ratio of 1.84, a current ratio of 1.92 and a debt-to-equity ratio of 0.01. Incyte Co. has a twelve month low of $50.27 and a twelve month high of $70.36. The stock has a market cap of $15.15 billion, a P/E ratio of 20.45, a price-to-earnings-growth ratio of 5.17 and a beta of 0.73. The firm’s fifty day simple moving average is $64.33 and its 200 day simple moving average is $60.26.

Incyte (NASDAQ:INCY) last announced its earnings results on Tuesday, July 30th. The biopharmaceutical company reported ($1.82) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.78 by ($2.60). The firm had revenue of $1.04 billion during the quarter, compared to the consensus estimate of $1.01 billion. Incyte had a return on equity of 0.75% and a net margin of 2.52%. The firm’s revenue was up 9.3% on a year-over-year basis. During the same period in the prior year, the company posted $0.77 EPS. As a group, research analysts predict that Incyte Co. will post 0.66 EPS for the current year.

Incyte Company Profile

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis.